Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 74, No 2 (2023)
Original paper
Submitted: 2022-12-28
Accepted: 2023-03-11
Published online: 2023-04-26
View PDF Download PDF file View HTML
Get Citation

Galanin-like peptide and its correlation with androgen levels in patients with polycystic ovary syndrome

Mustafa Demirpence1, Hamiyet Yilmaz Yasar1, Inanc Karakoyun2, Elif Merve Girgin2
DOI: 10.5603/EP.a2023.0026
·
Pubmed: 37155301
·
Endokrynol Pol 2023;74(2):197-202.
Affiliations
  1. Department of Endocrinology and Metabolic Diseases, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Türkiye
  2. Department of Medical Biochemistry, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Türkiye

open access

Vol 74, No 2 (2023)
Original Paper
Submitted: 2022-12-28
Accepted: 2023-03-11
Published online: 2023-04-26

Abstract

Introduction: We aimed to investigate serum galanin-like peptide (GALP) levels and their correlation with hormonal and metabolic parameters in patients with polycystic ovary syndrome (PCOS).

Material and methods: The study included 48 women (age range, 18–44 years) with a diagnosis of PCOS, and a control group that included 40 healthy females (age range, 18–46 years). Waist circumference, body mass index (BMI), and Ferriman-Gallwey score were evaluated and plasma glucose, lipid profile, oestradiol, progesterone, total testosterone, prolactin, insulin, dehydroepiandrosterone sulphate (DHEA-S), follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), 25-hydroxyvitamin D (25(OH)D), fibrinogen, d-dimer, C-reactive protein (CRP), and GALP levels were measured in all study subjects.

Results: Waist circumference (p = 0.044) and Ferriman-Gallwey score (p = 0.002) were significantly higher in patients with PCOS compared to the control group. Among the metabolic and hormonal parameters studied, only total testosterone was significantly higher in patients with PCOS (p = 0.002). Also, the serum 25(OH)D level was significantly lower in the PCOS group (p = 0.001). CRP, fibrinogen, and D-dimer levels were all similar between the 2 groups. Serum GALP level was significantly higher in PCOS patients (p = 0.001). GALP was negatively correlated with 25(OH)D (r = –0.401, p = 0.002) and positively correlated with total testosterone values (r = 0.265, p = 0.024). Multiple regression analysis revealed that both total testosterone and 25(OH)D significantly contributed to GALP levels.

Conclusions: Our study is the first in the literature to evaluate serum GALP levels in patients with PCOS. Increased GALP levels in PCOS and its association with total testosterone levels might show that GALP can act as an intermediary in increased GnRH-mediated LH release, which is one of the underlying pathogenetic mechanism of PCOS.

Abstract

Introduction: We aimed to investigate serum galanin-like peptide (GALP) levels and their correlation with hormonal and metabolic parameters in patients with polycystic ovary syndrome (PCOS).

Material and methods: The study included 48 women (age range, 18–44 years) with a diagnosis of PCOS, and a control group that included 40 healthy females (age range, 18–46 years). Waist circumference, body mass index (BMI), and Ferriman-Gallwey score were evaluated and plasma glucose, lipid profile, oestradiol, progesterone, total testosterone, prolactin, insulin, dehydroepiandrosterone sulphate (DHEA-S), follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), 25-hydroxyvitamin D (25(OH)D), fibrinogen, d-dimer, C-reactive protein (CRP), and GALP levels were measured in all study subjects.

Results: Waist circumference (p = 0.044) and Ferriman-Gallwey score (p = 0.002) were significantly higher in patients with PCOS compared to the control group. Among the metabolic and hormonal parameters studied, only total testosterone was significantly higher in patients with PCOS (p = 0.002). Also, the serum 25(OH)D level was significantly lower in the PCOS group (p = 0.001). CRP, fibrinogen, and D-dimer levels were all similar between the 2 groups. Serum GALP level was significantly higher in PCOS patients (p = 0.001). GALP was negatively correlated with 25(OH)D (r = –0.401, p = 0.002) and positively correlated with total testosterone values (r = 0.265, p = 0.024). Multiple regression analysis revealed that both total testosterone and 25(OH)D significantly contributed to GALP levels.

Conclusions: Our study is the first in the literature to evaluate serum GALP levels in patients with PCOS. Increased GALP levels in PCOS and its association with total testosterone levels might show that GALP can act as an intermediary in increased GnRH-mediated LH release, which is one of the underlying pathogenetic mechanism of PCOS.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

galanin-like peptide; polycystic ovary syndrome; androgen levels; vitamin 25(OH)D

About this article
Title

Galanin-like peptide and its correlation with androgen levels in patients with polycystic ovary syndrome

Journal

Endokrynologia Polska

Issue

Vol 74, No 2 (2023)

Article type

Original paper

Pages

197-202

Published online

2023-04-26

Page views

2183

Article views/downloads

525

DOI

10.5603/EP.a2023.0026

Pubmed

37155301

Bibliographic record

Endokrynol Pol 2023;74(2):197-202.

Keywords

galanin-like peptide
polycystic ovary syndrome
androgen levels
vitamin 25(OH)D

Authors

Mustafa Demirpence
Hamiyet Yilmaz Yasar
Inanc Karakoyun
Elif Merve Girgin

References (34)
  1. Spritzer PM, Santos BR, Fighera TM, Marchesan LB, Lecke SB. Intrinsic abnormalities of adipose tissue and adipose tissue dysfunction in PCOS. In: Diamanti-Kandarakis E. ed. Polycystic Ovary Syndrome, Challenging Issues in the Modern Era of Individualized Medicine. Elsevier 2022: 73–96.
  2. Bozkırlı E, Bakıner O, Ertörer E, et al. Insulin Resistance in Non-Obese Polycystic Ovary Syndrome Subjects and Relation with Family History of Diabetes Mellitus. Turk Jem. 2015; 19(2): 55–59.
    CrossRef
  3. Çakır E, Çakal E, Özbek M, et al. Polycystic Ovary Syndrome and the Relationship of Cardiovascular Disease Risk. Turk Jem. 2013; 17(2): 33–37.
    CrossRef
  4. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new? Adv Clin Exp Med. 2017; 26(2): 359–367.
    CrossRefPubMed
  5. Wołczyński S, Zgliczyński W. Abnormalities of the menstrual cycle. In: Zgliczyński W. ed. Large Interna — Endocrinology. 2nd edition. Medical Tribune Poland, Warsaw 2012: 561–567.
  6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
    CrossRefPubMed
  7. Esparza LA, Schafer D, Ho BS, et al. Hyperactive LH Pulses and Elevated Kisspeptin and NKB Gene Expression in the Arcuate Nucleus of a PCOS Mouse Model. Endocrinology. 2020; 161(4).
    CrossRefPubMed
  8. Li Y, Zhi W, Haoxu D, et al. Effects of electroacupuncture on the expression of hypothalamic neuropeptide Y and ghrelin in pubertal rats with polycystic ovary syndrome. PLoS One. 2022; 17(6): e0259609.
    CrossRefPubMed
  9. Mohr MA, Leathley E, Fraley GS. Hypothalamic galanin-like peptide rescues the onset of puberty in food-restricted weanling rats. J Neuroendocrinol. 2012; 24(11): 1412–1422.
    CrossRefPubMed
  10. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21: 1440–1447.
    CrossRefPubMed
  11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
    CrossRefPubMed
  12. Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4): 219–231.
    CrossRefPubMed
  13. Burt Solorzano CM, Beller JP, Abshire MY, et al. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids. 2012; 77(4): 332–337.
    CrossRefPubMed
  14. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016; 37(5): 467–520.
    CrossRefPubMed
  15. Wu S, Divall S, Nwaopara A, et al. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014; 63(4): 1270–1282.
    CrossRefPubMed
  16. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016; 37(5): 467–520.
    CrossRefPubMed
  17. Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014; 102(2): 460–468.e3.
    CrossRefPubMed
  18. Wehr E, Pilz S, Schweighofer N, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009; 161(4): 575–582.
    CrossRefPubMed
  19. Yildizhan R, Kurdoglu M, Adali E, et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009; 280(4): 559–563.
    CrossRefPubMed
  20. Irani M, Minkoff H, Seifer DB, et al. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab. 2014; 99(5): E886–E890.
    CrossRefPubMed
  21. Oh SoRa, Choe SYi, Cho YJ. Clinical application of serum anti-Müllerian hormone in women. Clin Exp Reprod Med. 2019; 46(2): 50–59.
    CrossRefPubMed
  22. He C, Lin Z, Robb SW, et al. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. Nutrients. 2015; 7(6): 4555–4577.
    CrossRefPubMed
  23. Kim JJu, Choi YM, Chae SJ, et al. Vitamin D deficiency in women with polycystic ovary syndrome. Clin Exp Reprod Med. 2014; 41(2): 80–85.
    CrossRefPubMed
  24. Hassan N, El-Orabi H, Eid Y, et al. Effect of 25-hydroxyvitamin D on metabolic parameters and insulin resistance in patients with polycystic ovarian syndrome. Middle East Fertil Soc J. 2012; 17(3): 176–180.
    CrossRef
  25. Mazloomi S, Sharifi F, Hajihosseini R, et al. Association between Hypoadiponectinemia and Low Serum Concentrations of Calcium and Vitamin D in Women with Polycystic Ovary Syndrome. ISRN Endocrinol. 2012; 2012: 949427.
    CrossRefPubMed
  26. Sánchez-Ferrer ML, Prieto-Sánchez MT, Corbalán-Biyang S, et al. Are there differences in basal thrombophilias and C-reactive protein between women with or without PCOS? Reprod Biomed Online. 2019; 38(6): 1018–1026.
    CrossRefPubMed
  27. Moin AS, Sathyapalan T, Diboun I, et al. Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome. Sci Rep. 2021; 11(1): 5320.
    CrossRefPubMed
  28. Gnanadass SA, Prabhu YD, Gopalakrishnan AV. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet. 2021; 303(3): 631–643.
    CrossRefPubMed
  29. Lawrence C, Fraley GS. Galanin-like peptide (GALP) is a hypothalamic regulator of energy homeostasis and reproduction. Front Neuroendocrinol. 2011; 32(1): 1–9.
    CrossRefPubMed
  30. Kageyama H, Kita T, Toshinai K, et al. Galanin-like peptide promotes feeding behaviour via activation of orexinergic neurones in the rat lateral hypothalamus. J Neuroendocrinol. 2006; 18(1): 33–41.
    CrossRefPubMed
  31. Kuramochi M, Onaka T, Kohno D, et al. Galanin-like peptide stimulates food intake via activation of neuropeptide Y neurons in the hypothalamic dorsomedial nucleus of the rat. Endocrinology. 2006; 147(4): 1744–1752.
    CrossRefPubMed
  32. Patterson M, Murphy KG, Thompson EL, et al. Microinjection of galanin-like peptide into the medial preoptic area stimulates food intake in adult male rats. J Neuroendocrinol. 2006; 18(10): 742–747.
    CrossRefPubMed
  33. Takenoya F, Guan JL, Kato M, et al. Neural interaction between galanin-like peptide (GALP)- and luteinizing hormone-releasing hormone (LHRH)-containing neurons. Peptides. 2006; 27(11): 2885–2893.
    CrossRefPubMed
  34. Rich N, Reyes P, Reap L, et al. Sex differences in the effect of prepubertal GALP infusion on growth, metabolism and LH secretion. Physiol Behav. 2007; 92(5): 814–823.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl